Newsroom

Sorted by: Latest

-

Bureau Veritas: Croissance organique leader dans le secteur à 6,5 % en 2025

COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI): Chiffres clés1 2025 › Chiffre d'affaires (CA) de 6 466,4 millions d'euros en 2025, en hausse de 6,5% sur une base organique (dont 6,3 % de croissance organique au quatrième trimestre). A taux de change constant, la croissance s’est établie à 7,3 % en glissement annuel et à 3,6 % sur une base reportée, › Résultat opérationnel ajusté de 1 052,9 millions d'euros, en hausse de 5,7 % par rapport aux 996,2 millions d'euros en 2024, soi...
-

Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025

COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency,...
-

DoorDash to Wind Down Deliveroo and Wolt Operations in Four Countries

SAN FRANCISCO & HELSINKI & LONDON--(BUSINESS WIRE)--DoorDash, Inc. (NASDAQ: DASH) today announced it is exiting four countries across its Deliveroo and Wolt brands: Qatar, Singapore, Japan, and Uzbekistan. The company will begin an orderly wind-down process in each country and will work closely with local teams and partners to support employees, merchants, consumers, riders, and couriers through the transition. These decisions follow a multi-month review of country-specific conditions and refle...
-

Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's Universi...
-

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 The syringe features a next-generation ergonomic design that enhances precision and control; includes an op...
-

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a...
-

Axelera AI obtient plus de 250 millions de dollars pour la croissance commerciale internationale

EINDHOVEN, Pays-Bas--(BUSINESS WIRE)--Axelera AI, leader européen du matériel d’accélération de l’IA, a annoncé son dernier tour de financement mené par Innovation Industries, avec la participation de fonds et d’investisseurs de premier plan, dont BlackRock et SiteGround Capital en tant que nouveaux investisseurs, ainsi que des investisseurs historiques tels que Bitfury, CDP Venture Capital, European Innovation Council Fund, la Société fédérale de participations et d’investissement de Belgique...
-

LAKE Investors Have Opportunity to Lead Lakeland Industries, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--LAKE Investors Have Opportunity to Lead Lakeland Industries, Inc. Securities Fraud Lawsuit with the Schall Law Firm...
-

Check Point與ControlPlane攜手合作,協助企業安全擴展AI規模,加速代理創新

倫敦--(BUSINESS WIRE)--(美國商業資訊)-- 專注於AI安全和開發、安全性和作業(DevSecOps)的諮詢公司ControlPlane與網路安全解決方案的先驅和全球領導者Check Point Software Technologies Ltd.今日宣布達成策略合作,旨在幫助企業安全地大規模部署大型語言模型(LLM)和代理式AI系統。 此次合作將提供一個全面且符合監理要求的安全框架,旨在降低風險、保護敏感資料,並幫助企業自信地從AI實驗過渡到生產部署。透過將Check Point的AI原生威脅防禦平台與ControlPlane在雲端原生架構和DevSecOps方面的深厚專長結合,企業可以安全地部署AI,而不會阻礙創新。 隨著企業將AI計畫從試點推進到實際應用階段,他們面臨日益嚴重的「AI準備差距」。諸如提示注入攻擊、未經授權的存取、資料外洩和模型濫用等新興威脅帶來了傳統安全控制措施無法因應的風險。世界經濟論壇指出,87%的安全主管認為AI相關漏洞是成長最快的網路風險,凸顯了建構有針對性的AI安全解決方案的迫切性。 ControlPlane已在一家監理嚴格的金融服務機...
-

Urteil in Klarnas Kartellklage gegen Google in Höhe von 8,3 Milliarden US-Dollar wird in Kürze erwartet

STOCKHOLM--(BUSINESS WIRE)--Die Klarna Group plc (NYSE: KLAR) gibt bekannt, dass das schwedische Patent- und Markengericht (Patent- och marknadsdomstolen) voraussichtlich am 15. April 2026 sein Urteil im Kartellschadensersatzverfahren fällen wird, das die Klarna-Tochter PriceRunner International AB gegen Google LLC und Google Ireland Limited angestrengt hat. Der Prozess, der vom 20. Oktober bis zum 19. Dezember 2025 dauerte, betraf die Klage von PriceRunner auf Schadenersatz in Höhe von rund 8,...